Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

Core Insights - Highmark Blue Cross Blue Shield has issued a positive coverage policy for Lucid Diagnostics' EsoGuard® Esophageal DNA Test for non-invasive screening of esophageal precancer and cancer in New York state, marking a significant milestone for the company [1][2] - The decision is expected to set a precedent for other commercial insurers to follow, enhancing the accessibility of EsoGuard testing across the country [2] - Lucid Diagnostics focuses on patients with gastroesophageal reflux disease (GERD), who are at risk of developing esophageal precancer and cancer, and aims to prevent cancer through early detection [3] Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., specializing in non-invasive diagnostic tools [3] - The EsoGuard® Esophageal DNA Test is the first and only commercially available tool designed for early detection of esophageal precancer in at-risk patients [3]